INTRODUCTION {#sec1-1}
============

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the increased production of autoantibodies by systemic clinical manifestation and damage to multiple organs. This study aimed at analysing the relationship between serum levels of macrophage-derived chemokine (MDC), and matrix metalloproteinase-9 (MMP-9) and disease activity of patients with SLE in order to evaluate their roles in the pathogenesis and course of the disease as well as their diagnostic values.

METHODS {#sec1-2}
=======

Subjects {#sec2-1}
--------

Diagnosis of SLE was established according to the 1997 revised American Rheumatism Association Criteria[@ref1], and disease activity was evaluated by the SLEDAI (SLE Disease Activity Index).[@ref2] The patients with SLE (32 women and 4 men, aged 11-61 yrs) were divided into 2 groups: 13 SLE patients with renal disease and 23 SLE patients without renal disease according to proteinuria (++↑ or \>0.5g/d); 23 active course patients and 13 inactive course patients were evaluated using the SLEDAI standard, and active disease was indicated by SLEDAI score of more than 8 points; 23 SLE patients with arthritis and 13 without the lesion according to articular damage. 30 sex and age matched healthy volunteers were recruited as controls.

Serum {#sec2-2}
-----

Three milliliters of venous peripheral blood were collected from each subject, centrifuged to get serum, and then stored at -80ºC. Nine serum samples were collected from patients taking corticosteroid three or four weeks later. The concentrations of MDC and MMP-9 were measured by ELISA respectively. ELISA kits for HGF, MDC and MMP-9 were purchased from R&D Systems Inc (Catalog No: DMD00, DMP00). Assays were performed according to the manufacturer's instructions.

Statistical analysis {#sec2-3}
--------------------

All the results were presented as mean±standard deviatioin. The differences were tested for statistical significance by Student's *t* test and relative risk. A probability (*P*) less than 0.05 was considered as significantly different.

RESULTS {#sec1-3}
=======

Significantly decreased serum levels of MDC and MMP-9 was found in SLE patients as compared to those in controls, 450.95±76.76 pg/ml vs 606.23±23.71 pg/ml (*P*\<0.001) and 108.52±113.23 ng/ml vs 352.25±155.01ng/ml (*P*\<0.001) respectively. Serum levels of MDN and MMP-9 were markedly lower in active patients than those with inactive disease, namely 393.98±53.73pg/ml vs 555.40±196.07 pg/ml (*P*\<0.001), and 71.70±66.24 ng/ml vs165.80±145.82 ng/ml (*P*\<0.05) respectively. Serum levels of MDC and MMP-9 were decreased in patients with renal damage than those without the damage, 366.81±56.25 pg/ml vs 496.85±114.55 pg/ml (*P*\<0.001), and 72.08±56.31ng/ml vs 141.93±140.55 ng/ml (*P*\<0.05) respectively. Markedly lower serum level of MDC was found in patients with arthritis than those without the damage, 386.43±48.79 pg/ml vs 569.25±199.47 pg/ml (*P*\<0.001), but serum level of MMP-9 has no significant difference in these two groups (*P*\>0.05). Relative analysis showed that no positive correlation was found among the serum level of MDC and SLEDAI (*r* =0.205 *P*\>0.05), but serum level of MMP-9 showing a negative correlation with SLEDAI (*r* = −0.41 *P*\<0.01), as [Table-I](#T1){ref-type="table"} and [Table-II](#T2){ref-type="table"}.

###### 

The comparison of serum level of MDC between SLE patients and controls

  Group              n    x̄±s (pg/ml)     t value   P value
  ------------------ ---- --------------- --------- ---------
  Controls           30   606.23±23.71    10.63     \<0.001
  SLE patients       36   450.95±76.76              
  Renal damage       13   366.81±56.25    3.68      \<0.001
  No renal damage    23   496.85±114.55             
  Active             23   393.98±53.73    3.72      \<0.001
  Inactive           13   555.40±196.07             
  SLEDAI\>8          23   389.46±57.88    3.69      \<0.001
  SLEDAI≤8           13   538.81±168.29             
  Arthritis          23   386.43±48.79    4.13      \<0.001
  No arthritis       13   569.25±199.47             
  Before treatment   9    163.91±48.36    6.72      \<0.001
  After treatment    9    452.78±102.99             

###### 

The comparison of serum level of MMP-9 between SLE patients and controls.

  Group              n    x̄±s (ng/ml)     t value   P value
  ------------------ ---- --------------- --------- ---------
  Controls           30   352.25±155.01   7.92      \<0.001
  SLE patients       36   108.52±113.23             
  Renal damage       13   72.08±56.31     2.17      \<0.05
  No renal damage    23   141.93±140.55             
  Active             23   71.70±66.24     2.98      \<0.05
  Inactive           13   165.80±145.82             
  SLEDAI\>8          23   80.29±71.61     2.20      \<0.05
  SLEDAI≤8           13   152.45±149.80             
  Arthritis          23   103.37±126.35   0.40      \>0.05
  No arthritis       13   117.32±89.40              
  Before treatment   9    114.41±92.40    2.00      \<0.05
  After treatment    9    245.64±196.57             

DISCUSSION {#sec1-4}
==========

SLE is a complicated autoimmune disease characterized by various immunological abnormalities, including polyclonal activation of circulating B lymphocyte that produce a large quantity of autoreactive antibodies, the abnormality of T lymphocyte and IC deposition. During the process, many chemokines and their receptors play an important regulating role.[@ref3]

If monocyte/macrophage releases IL-10 continuously, it will result in division of Th cell to Th2 cell. If monocyte/macrophage releases IL-12 continuously, it will promote transformation of Th cell to Th1 cell. So we focus on cytokines derived from monocyte/macrophage and this will demonstrate the role of chemokines in SLE pathogenesis.

MDC, a CC chemokine, is a potent chemoattractant which activated Th2 lymphocytes via the chemokine receptor CCR4,[@ref4] and its receptor CC chemokine receptor 4 (CCR4) preferentially expressed on Th2 cells. Th2 type cytokines IL-4 and IL-13 downregulated the production of MDC. This may partially contribute to maintaining Th1/Th2 balance.[@ref5] Dendritic cells, B lymphocytes and macrophages all produced MDC constitutively, while NK cells, monocytes, and CD4^+^ T lymphocytes produce MDC upon stimulation. IFN-γ can also suppress MDC expression in monocyte, macrophage, and dendritic cells.[@ref6] Because many immune cells can produce MDC and MDC can chemoattract many immune cells, MDC may be essential in SLE pathogenesis. Serum level of MDC in 36 SLE patients was tested and it was discovered that serum level of MDC was significantly decreased in patients as compared to those in controls, and markedly decreased in patients with active disease than those without these diseases. All these demonstrated MDC was involved in SLE process, it might be relevant to SLE activity, and it might be a new sensitive marker. Dolff[@ref7] reported that SLE was a Th2 type disease, but our results showed the significantly decreased serum level of MDC. Whether SLE is not the dominant Th2 type disease remains to be further studied.

MMP-9 was involved in inflammation and immune system dysfunctions. Besides immunologic abnormalities, SLE also presents chronic inflammatory components. Therefore, a role of MMP-9 in SLE pathology might be suspected.[@ref8] Serum level of MMP-9 in 36 SLE patients was tested and it was discovered that serum level of MMP-9 was significantly decreased in patients as compared to those in controls, and was lower in patients with active disease than those with inactive disease. A negative relation between serum level of MMP-9 and SLEDAI was found, which may reflect dynamic change of SLE.

SLE tends to damage multiple organs, including the kidney and article. Our test showed the serum levels of MDC and MMP-9 were decreased in patients with renal damage than those without the damage, and the serum level of MDC was markedly decreased in patients with arthritis than those without the damage. So MDC and MMP-9 may be involved in the pathogenesis of lupus nephritis and seemed to be markers of renal damage, and MDC may be involved in the pathogenesis of arthritis and seemed to be a new sensitive marker of article damage. As Garcia[@ref9] and his colleagues reported, they found that MDC was critically involved in the development at anti-GBM GN from acute glomerular injury to irreversible tissue damage. Sato[@ref10] and his colleagues investigated the serial changes of glomerular metalloproteinase activity in antithymocyte-induced glomerulonephritis in rats and found attennated glomerular MMP-9 activity.

The serum levels of MDC and MMP-9 in 9 SLE patients taking corticosteroid 3 or 4 weeks later were examined and it was found that clinical symptoms were relieved, indexes of lab test improved, serum level of MDC and MMP-9 increased. The increased serum level of MDC remains to be studied, but the increased serum level of MMP-9 may explain that glucocortisone influenced the release of MMP-9 from blood circulation.[@ref11] It is thought that the increased serum level of MDC and MMP-9 may demonstrate the lupus improvement, so the serum levels of MDC and MMP-9 may serve as markers for the determination of disease progression or improvement.

MDC and MMP-9 were involved in the pathogenesis of SLE. What is their relationship remains to be studied. Vermaelen[@ref12] and his colleagues reported that the specific absence of MMP-9 activity inhibited the development of allergic airway inflammation by impairing the recruitment of DCs into airways and the local production of DC-derived chemokines. At present, DCs are the most powerful antigen presenting cells and the main resource of MDC.[@ref13] The functional disorder antigen presenting cells[@ref14] and the reduced DCs[@ref15] are in existence in patients with SLE has been reported and the proportion of DCs in peripheral blood showed a negative correlation with disease activity.[@ref15] From our study it has been shown that serum levels of MDC and MMP-9 were significantly decreased in SLE patients. Whether this mechanism may also be involved in SLE pathogenesis, it depends on further accumulation of clinical researches.

CONCLUSION {#sec1-5}
==========

SLE is an autoimmune disease. The useful measurement to cure this disease is Prednisone. When symptom ease, the dosage of Prednisone should be reduced. At this time, patient's condition prefers to relapse, especially during 10-15mg a day to take. So the combing between Traditional and Western medicine is very important. The combination can control its deterioration and reduce its relapse so it is better to cure it.

Limitations of the Study {#sec2-4}
------------------------

Small sample size was one of the important limitations of this study.

This study was supported by grants from Natural Science Foundation of Inner Mongolia Autonomous Region of China (200711020948), Medical and Health Research Project of Health and Family Planning commission of Inner Mongolia Autonomous Region of China (201303047), Scientific Research Program at Universities of Inner Mongolia Autonomous Region of China (NJZY14146), Supported by Natural Science Foundation of Inner Mongolia Autonomous Region of China (2014MS08146).

***Declaration of interest:*** The authors state that they have no conflict of interest.
